Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results

nternal managerial purposes because we believe such measures are one important indicator of the strength and the performance of our business as they provide a link to operating cash flow. We also believe that analysts and investors use such measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss for each of the three-month periods ended December 31, 2008 and 2007 was approximately $0.5 million. Compared to the year-ago period, an improvement in gross profit rate and a decrease in cash operating expenses were about offset by a decrease in sales. Our non-GAAP operating performance improved from a loss of approximately $1.5 million for the nine months ended December 31, 2007 to a loss of approximately $0.5 million for the same period in 2008. We attribute this improvement in non-GAAP operating performance to the increase in sales and an improvement in gross profit rate, offset partially by an increase in cash operating expenses.

                            Three Months Ended       Nine Months Ended
                                December 31,              December 31,
                             2008         2007         2008         2007

    Gross Profit
      GAAP gross
       profit           $2,853,298   $2,939,359  $10,042,269   $7,664,323
      % of sales                84%          79%          85%          79%
      SFAS 123(R)
       compensation          8,879        9,008       34,132       18,695
       expenses             12,436       13,277       38,283       41,882
      Non-GAAP gross
       profit            2,874,613    2,961,644   10,114,684    7,724,900
    Operating Expenses
      GAAP operating
       expenses          3,774,118    3,868,656   12,012,296  $
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... first time, chemists have succeeded in measuring vibrational motion ... The study reveals how vibration of a single molecule ... , The study was performed at the University of ... University of Jyvskyl works as a visiting fellow under ... study. The second team was lead by Professor Eric ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... 22, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic ... that the company will be exhibiting at the 61st ... of Cardiology (ACC) in Chicago, March 24-27, Booth #15084. ... is the first and only multiple biomarker blood test ...
... The new Dynaflow Resolve System was developed in close ... demand for a simpler technology capable of complex perfusion ... perfusion system that enables novel experimental protocols by allowing ... type, and any compound. The new and improved system ...
... March 21, 2012 AtheroNova Inc. (OTCBB: AHRO), a ... compounds to regress atherosclerotic plaque, today announced that it ... development stage company, no revenues were recognized in the ... were $2,560,235 for 2011 compared to $2,679,435 in 2010. ...
Cached Biology Technology:FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays 2AtheroNova Releases 2011 Financial Results 2AtheroNova Releases 2011 Financial Results 3
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... A rose by any other name may smell as sweet, but ... is booted out of the grass family, where does it go? ... recently investigated the evolution of grasses, one of the most economic ... an early diverging grass genus, Anomochloa , and comparing it ...
... could determine the amount of carbon dioxide emitted from soils ... this week in Nature Geoscience . Researchers at ... Forestry & Environmental Studies have found that as global temperatures ... converting carbon in soil into carbon dioxide, which is a ...
... WEST LAFAYETTE, Ind. - Just months after the soybean ... a long-sought gene that controls the plant,s main stem ... types of soybean plants that will allow producers to ... Ma (Jen-Shin Ma), an assistant professor of agronomy, used ...
Cached Biology News:What is a grass? 2Microbes contribute less to climate warming 2Gene discovery may lead to new varieties of soybean plants 2
... F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α ... containing both a double bond at ... group at C-15. Similar to 15(S)-latanoprost, ... a potential impurity in most commercial ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
Biology Products: